|Tested species reactivity||Mouse, Rat|
|Published species reactivity||Human|
|Host / Isotype||Goat / IgG|
|Immunogen||Synthetic peptide sequence (REFLGKSEPEHQH) corresponding to the C-terminus amino acids of ABHD12|
|Purification||Antigen affinity chromatography|
|Storage buffer||TBS, pH 7.3, with 0.5% BSA|
|Contains||0.02% sodium azide|
|Storage Conditions||-20° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|Western Blot (WB)||0.3-1 ug/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Western Blot (WB)||See 1 publications below|
This antibody is predicted to react with human based on sequence homology.
This gene encodes an enzyme that catalyzes the hydrolysis of 2-arachidonoyl glycerol , the main endocannabinoid lipid transmitter that acts on cannabinoid receptors, CB1 and CB2. The endocannabinoid system is involved in a wide range of physiological processes, including neurotransmission, mood, appetite, pain appreciation, addiction behavior, and inflammation. Mutations in this gene are associated with the neurodegenerative disease, PHARC , resulting from an inborn error of endocannabinoid metabolism. Alternatively spliced transcript variants encoding different isoforms have been noted for this gene.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Two novel mutations in ABHD12: expansion of the mutation spectrum in PHARC and assessment of their functional effects.
PA5-18982 was used in western blot to study two novel ABHD12 mutations associated with PHARC
|Chen DH,Naydenov A,Blankman JL,Mefford HC,Davis M,Sul Y,Barloon AS,Bonkowski E,Wolff J,Matsushita M,Smith C,Cravatt BF,Mackie K,Raskind WH,Stella N,Bird TD||Human mutation (34:1672)||2013|